Careers at Guided Therapeutics

HomeLuVivaPipelinePublicationsInvestorsNewsContactE-mail

News Releases

Board of Directors

Audit Committee Charter

Compensation Committee Charter

Key People

Regulatory Filings

Stock Quote

 

   

Information for Investors

  Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level.  The company’s first planned product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.  In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for Barrett’s Esophagus using the technology platform.

March 27 Conference Call


Investor Relations

Cameron Associates

Alison Zeigler 212-554-5469

 

 

  “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this web site that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and subsequent quarterly reports.

©2014 Guided Therapeutics, Inc.

5835 Peachtree Corners East

Suite D

Norcross, GA 30092

770-242-8723

770-242-8639 - Fax

www.guidedinc.com

info@guidedinc.com

Terms of Service